Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07658573
Active, not recruiting Observational

AI Multimodal Model for Predicting CRPC Progression Risk

NCT07658573 · tracked via the Priya Life Science China tracker
Sponsor
Guangxi Medical University
Phase
Observational
Started
2025-06-01
Last updated
2026-06-22

Condition(s) studied

Prostate CancerCastration-Resistant Prostate Cancer

Study summary

This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease. The study will use pre-treatment MRI images, biopsy pathology slides, and clinical data collected from patients who received either hormone therapy (ADT) or radical prostatectomy surgery. By integrating these different types of data, the AI model is designed to help doctors identify high-risk patients earlier, personalize treatment plans, and ultimately improve patient outcomes. This is a multicenter, retrospective study that will analyze data from over 500 patients with at least 24 months of follow-up. The performance of the model will be evaluated using standard accuracy metrics.

Eligibility

Sex
MALE
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * (1) Male, age ≥18 years; (2) Pathologically confirmed newly diagnosed advanced prostate cancer; (3) Received at least 6 months of androgen deprivation therapy OR underwent radical prostatectomy; (4) Have complete baseline MRI (T2WI, DWI, ADC) and biopsy pathology data; (5) Have complete follow-up records (at least 24 months). Exclusion Criteria: * (1) Missing clinical information; (2) MRI images of poor quality or missing key sequences; (3) Poor quality pathological specimens; (4) Lost to follow-up or incomplete data during follow-up; (5) Concurrent other malignant tumors; (6) Prior anti-tumor therapy.

Primary outcome measure(s)

  • Prediction of CRPC Progression Risk in the ADT Treatment Group — Minimum 24 months of follow-up
    Performance of the multimodal AI model in predicting progression to castration-resistant prostate cancer in patients with newly diagnosed advanced prostate cancer who received at least 6 months of androgen deprivation therapy. Metrics include AUC, accuracy, sensitivity, and specificity.
  • Prediction of CRPC Progression Risk in the Radical Prostatectomy Group — Minimum 24 months of follow-up
    Performance of the multimodal AI model in predicting progression to castration-resistant prostate cancer in patients with newly diagnosed advanced prostate cancer who underwent radical prostatectomy. Metrics include AUC, accuracy, sensitivity, and specificity.

Trial sites (1)

FacilityCityRegionStatus
Guangxi Medical University First Affiliated Hospital Nan'ning China

More Guangxi Medical University trials in China

Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma Recruiting
AI Multimodal Model for Liver Cancer Diagnosis and Prognosis Active, not recruiting
Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma Recruiting
Intelligent Screening and Precision Diagnosis of Prostate Cancer Based on Multimodal Data Active, not recruiting
Adjuvant TACE in HCC With High-risk Recurrence Factors Recruiting

Other trials for the same condition

A Study of SHR-4394 Injection in Subjects With Prostate Cancer Recruiting
Application of Ultrasound Radiomics in Ultrasound Fusion Targeted Prostate Biopsy Active, not recruiting
Comparison of MRI Artificial Intelligence-guided cTB Versus Routine cTB in Prostate Cancer Diagnosis Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation Recruiting
Clinically Actionable Tumor-Associated Antigens in Prostate Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07658573 on ClinicalTrials.gov ↗ ← All trials in China